GRAVITAS
Research type
Research Study
Full title
GLP-1 Receptor Agonist interVention for poor responders after barIAtric Surgery: The GRAVITAS trial
IRAS ID
164479
Contact name
Stephen Bloom
Contact email
Eudract number
2014-003923-23
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are very effective treatments for type 2 diabetes mellitus associated with obesity. They cause approximately 30% weight loss and substantial improvements in blood glucose control. However, for some of our patients these operations do not work as well; these patients’ diabetes does not improve as much as they either do not lose enough weight to start with or they regain substantial amounts.
We and others have found that these two procedures cause reductions in blood glucose and weight by producing high a mounts of a hormone called glucagon like peptide-1 or GLP-1 for short. In addition, patients who do not do well after surgery produce less of this hormone compared to those who have done well. GLP-1 can be given as an injection for the routine treatment of patients who have diabetes but do not undergo bariatric surgery, and results in reductions in blood glucose and/or weight. We therefore wondered whether giving patient who do not do well after surgery a daily injection of GLP-1 may reduce their blood glucose and weight. We are therefore performing this trial in which we will randomly allocate half of the patients to receive this hormone and half to receive placebo (saline) in order to find out whether those on the hormone do better in terms of blood glucose and weight.
REC name
London - West London & GTAC Research Ethics Committee
REC reference
15/LO/0780
Date of REC Opinion
26 Jun 2015
REC opinion
Further Information Favourable Opinion